Russian drugmakers see delays in investment projects due to geopolitical tensions and sanctions

4 September 2018

Russia’s top pharmaceutical companies may suspend implementation of projects which involve the expansion of their production capacities, due to existing sanctions regimes and ongoing geopolitical tensions with Western countries, according to recent statements from the heads of some leading companies, reports The Pharma Letter’s local correspondent.

For example, Biocad is currently unable to finish the construction of its plant in St Petersburg, mainly due to serious delays in the supplies of equipment and machinery for the plant by the firm’s Western partners.

This has already been confirmed by Dmitry Morozov, chief executive of the company. A new plant, which is currently being built by the company, should produce at least 13 drugs, with the value of the investment in the project estimated at 3 billion roubles (~$46 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK